Forward Ventures Funds Tioga Pharmaceuticals

Tioga Pharmaceuticals has been formed to develop a medicine (asimadoline) to treat pain in irritable bowel syndrome (IBS) patients and other gastrointestinal diseases. IBS represents a disease of significant unmet need with 70 million sufferers in the United States and Europe. Asimadoline is a novel small molecule discovered and developed by Merck KGaA of Darmstadt, Germany. In clinical trials the medicine has shown promising safety and efficacy in men and women with either constipation related or diarrhea related IBS.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=248832)